Annual or Biannual Boosters Are Optimal for Fighting Endemic COVID-19, Study Shows
A team of scientists led by faculty at the Yale School of Public Health and the University of North Carolina at Charlotte finds that updated boosters administered on an annual or biannual basis greatly reduce the long-term risk of infection from endemic COVID-19.
Yuval Kluger appointed Anthony N. Brady Professor of Pathology
Yuval Kluger, who works in the broad fields of bioinformatics, machine learning, and applied mathematics to develop new approaches for analyzing large biological data sets, was recently appointed the Anthony N. Brady Professor of Pathology.Source: Yale News
Large Genetic Study Expands Links Between DNA Variations and Problematic Drinking
A genome-wide analysis of over 435,000 individuals of European ancestry has revealed 19 new locations in the human genome where common DNA variations significantly raise risk for problematic drinking. It also linked pathological drinking with elevated risk of many psychiatric disorders, including depression and schizophrenia.Source: Brain & Behavior Research Foundation
Rapid Data Sharing and Genomics Vital to China Virus Response
Virus genomics is playing a critical role in combating an emerging respiratory virus in China that has international health officials on alert. Yale School of Public Health scientist and genomics expert Nathan Grubaugh explains what's happening.
Examining Genomics in the Treatment of Cervical Cancer
Could targeted therapy play a larger role in the treatment of cervical cancer in the near future? Researchers from Yale Cancer Center believe they are one step closer to finding out, according to new study findings published in the Proceedings of the National Academy of Sciences.Source: Cure Today
Yale Launches Comprehensive DNA Sequencing Project, With Aim of Predicting, Preventing, and Treating Gene-related Diseases
Generations, a collaboration between Yale School of Medicine and Yale New Haven Health System, is one of the largest DNA sequencing projects of its kind in the United States.
Genome screen uncovers new targets for cancer immunotherapy
A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale Cancer Center researchers report Aug. 22 in the journal Cell.
Genetically Sequencing DNA Could Yield Patient Care Insights
Yale Medicine and Yale New Haven Health, along with several other institutions across the country, are beginning to offer whole-exome sequencing as part of very large studies designed to discover more information about the role of genes, and gene variants, in disease.Source: Yale Medicine
Yale-led project connects social networks and the microbiome
Led by Nicholas Christakis, Yale’s Sterling Professor of social and natural science and the director of the Human Nature Lab, the Microbiome Biology and Social Networks in the Developing World project launched Jan. 1. The project is funded by a $3.54 million grant from the NOMIS Foundation and will take place in the Copan region of Honduras.Source: Yale Daily News
Yale scientists study genes misidentified as ‘non-protein coding’
The human genome contains regions that “code” for proteins, which means they have instructions to make protein molecules with specific functions in the body. But Yale researchers have discovered several protein-coding genes that were misidentified as non-protein-coding, and one in particular that plays a key role in the immune system.
Newly Funded Chromatin Study Could Shed Light on Genome
Combining engineering, biology and physics, three Yale researchers have received a four-year grant from the National Science Foundation (NSF) to study chromatin in yeast cells. They aim to better understand chromatin's properties and use the genome as a device to measure and record dynamic, transient chromatin states.
Yale study: Mapping tumors’ genes doesn’t improve survival
In this age of personalized medicine, sequencing the genes in a patient’s tumor can reveal mutations that may be treatable with targeted medications. But a new Yale School of Medicine-led study published Aug. 7 in the Journal of the American Medical Association shows that testing for many such mutations does not improve the chances of a patient’s survival. Data was analyzed from 5,688 patients with non-small cell lung cancer who were treated in a community cancer clinic rather than a large research institution. About 15 percent received broad-based sequencing of the tumor’s genome; the rest were tested only for two mutations, known as EGFR and ALK, for which medications are available. Incorporating variables into the analysis, the researchers found that mortality rates after 12 months were 41.1 percent for those who had the broad-based sequencing and 44.4 percent for those who just had the tests for EGFR and ALK.Source: New Haven Register
Would Routine Genomic Testing For Cancer And Heart Risk Make Economic Sense?
If all adults were to have their genes sequenced during their annual physicals this year, the vast majority of us would not learn anything that would change our medical routines going forward. But an estimated 1% of Americans—at least 3 million people—would find genetic abnormalities that greatly raise their risk of cancer or heart disease. And that, says Yale School of Medicine genetics expert Michael Murray, would make all of that testing worth it, not only to those individuals, but to society as a whole. Even if each person had just 10 genes tested, the benefits would outweigh the costs, argues Murray, who wrote an article published today in the journal Annals of Internal Medicine that urges health systems to embrace routine genomic testing. That’s because such testing would reveal “actionable” gene mutations—well-known risks for diseases that can be avoided with specific screening or prevention methods.Source: Forbes